Veritas In Silico ＜130A＞ announced on the 23rd that it has entered into a joint development and commercialization agreement with Liverpool ChiroChem (LCC) for RNA-targeted small molecule Pharmaceuticals.

Starting from July 2024, the company will conduct screening analyses for 10 mRNA targets, expected to be applied to cancer diseases, rare diseases, central nervous system diseases, and infections, using over 1,000 new chiral fragments from LCC's chemical platform PACETM via its drug discovery platform ibVIS, with good results obtained. In the future, as a collaborative drug discovery business with LCC, projects will be selected around these 10 mRNA targets to obtain promising ligands (substances that could become new drugs) from hit compounds, aiming to create the latest and highest-level global assets (fragment compounds) and further commercialization.

This contract signing corresponds to the 'acquisition of new contracts' set as a KPI in the company's growth strategy and marks the achievement of the first target of 'new contracts to be acquired (target of 4 contracts)' announced in the December 13, 2024 'Announcement of Revision of Financial Estimates for the Fiscal Year Ending December 2024'. It should be noted that there will be no revenue generated from this contract signing as it was arranged not to exchange a contract signing fee.